+

US6011070A - Slow-onset, long-lasting dopamine reuptake blockers - Google Patents

Slow-onset, long-lasting dopamine reuptake blockers Download PDF

Info

Publication number
US6011070A
US6011070A US08/911,778 US91177897A US6011070A US 6011070 A US6011070 A US 6011070A US 91177897 A US91177897 A US 91177897A US 6011070 A US6011070 A US 6011070A
Authority
US
United States
Prior art keywords
lower alkyl
group
compound
substituted
amine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
US08/911,778
Other languages
English (en)
Inventor
Mark Froimowitz
Kuo-Ming Wu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allelix-Pharm-Eco LP
Original Assignee
Allelix-Pharm-Eco LP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allelix-Pharm-Eco LP filed Critical Allelix-Pharm-Eco LP
Priority to US08/911,778 priority Critical patent/US6011070A/en
Assigned to ALLELIX-PHARM-ECO L.P. reassignment ALLELIX-PHARM-ECO L.P. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: WU, KUO-MING
Application granted granted Critical
Publication of US6011070A publication Critical patent/US6011070A/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C211/39—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton
    • C07C211/41—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems
    • C07C211/42—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems with six-membered aromatic rings being part of the condensed ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Definitions

  • Drug abuse is a pervasive problem in modern society.
  • the most abusable and addictive drugs are those which have fast onsets and short durations of action.
  • Cocaine for example, has an onset of action on the order of seconds and of synaptic dopamine and this is associated with feelings of euphoria and well being.
  • the immediate, short term effect of cocaine is to increase synaptic levels of dopamine
  • chronic use of cocaine may result in depleted levels of synaptic dopamine in the absence of cocaine. This has been associated with ahedonia and chronic cocaine craving upon cessation of cocaine use.
  • One strategy for treating cocaine abusers is to administer an alternative dopamine reuptake blocker which will raise synaptic levels of dopamine.
  • Known methods for raising reduced levels of synaptic dopamine and thus, reducing the craving for cocaine include the use of compounds that block dopamine reuptake. (Rosenzweig-Lipson et al., Psychopharmacology 10:186 (1992)).
  • dopamine reuptake blockers are limited to a duration of between about two and four days (Rosenzweig-Lipson et al., Psychopharmacology 10:186 (1992)). Even a duration of two to four days requires a relatively regimented schedule for patients, who, because of their affliction, may not adhere to the prescribed dosages.
  • drugs which block the reuptake of dopamine are also believed to have other potential utilities such as for the treatment of attention deficit hyperactivity disorder and Parkinson's disease.
  • the present invention is a method of treating an individual who abuses cocaine with N,N-dialkyl 3-phenyl-1-indamines.
  • Novel N,N-dialkyl 3-phenyl-1-indanamines are reported in the co-pending U.S. patent application filed on Aug. 15, 1997, entitled NOVEL COMPOUNDS FOR TREATING COCAINE ABUSE Ser. No. 08/911,864, the entire teachings of which are incorporated herein by reference.
  • the present invention is a method of treating an individual for cocaine abuse.
  • the method comprises administering to the individual a therapeutically effective amount of a compound or mixture of compounds represented by Structural Formula (I): ##STR1##
  • Ring A is selected from the group consisting of an aryl group, a substituted aryl group, a heteroaryl group and a substituted heteroaryl group. Ring A is preferably phenyl, naphthyl or indolyl. More preferably, Ring A is phenyl.
  • R1 is selected from the group consisting of a lower alkyl group and a substituted lower alkyl group.
  • R1 is methyl.
  • R2 is selected from the group consisting of a lower alkyl group, a substituted lower alkyl group, --(CH 2 ) n -aryl and --(CH 2 ) n -(substituted aryl), wherein n is an integer from one to about 3.
  • R2 is a benzyl group.
  • R2 is preferably a C1 to C4 straight or branched chain lower alkyl group, for example, methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl or t-butyl.
  • R3 and R4 are independently selected from the group consisting of --H, a lower alkyl group and a substituted lower alkyl group. R3 and R4 are preferably each --H.
  • Ring B is unsubstituted or substituted with one, two or three substituents other than hydrogen.
  • Suitable substituents include halogen, an alkyl group, a substituted alkyl group, hydroxy, (lower alkyl)-O--, (substituted lower alkyl)-O--, --CN, --NO 2 , amine, (lower alkyl) amine, (substituted lower alkyl) amine, (di-lower alkyl) amine and (substituted di-lower alkyl) amine.
  • the present invention is a method of treating an individual with a disease involving depletion of synaptic dopamine.
  • a disease involving depletion of synaptic dopamine examples include cocaine abuse, Parkinson's disease or attention deficit hyperactivity disorder.
  • the method comprises administering to the individual a therapeutically effective amount of a compound or a mixture of compounds represented by Structural Formula (I).
  • the methods of treating cocaine abuse, Parkinson's disease and attention deficit hyperactivity disorder disclosed herein utilize compounds which block the reuptake of dopamine and which have a slow onset of action. Thus, the abuse potential by individuals being treated is minimized compared with drugs which have a more rapid onset of activity.
  • N,N-dialkyl 3-1-indanamines block the effects of cocaine in mammals.
  • N,N-dimethyl-3-(3',4'-dichlorophenyl)-1-indanamine, Compound 1 produces a dose-dependent decrease in cocaine self-administration in rhesus monkeys (Example 7) and Compounds 2 and 7 block cocaine induced locomotor activity in mice (Example 3).
  • N,N-dialkyl 3-phenyl-1-indanamines e.g., Compounds 1-3
  • stimulate locomotor activity when administered at levels of 10 mg/kg and less (Examples 2 and 5).
  • the induction of activity is slow, occurring after twenty to thirty minutes (Example 2).
  • N,N-dialkyl 3-phenyl-1-indanamines are pharmacologically active for longer periods of time in mammals than N-monoalkyl 3-phenyl-1-indanamines.
  • Compound 1 has been found to stimulate locomotor activity in primates for five to seven days (Example 5), while Compound 5, its monoalkyl analog, stimulates locomotor activity for only about two to four days (Example 5).
  • N,N-dialkyl 3-phenyl-1-indanamines are effective compounds in treating individuals who abuse cocaine.
  • these compounds can also be used as drugs with long-lasting effects for individuals who require treatment with dopamine reuptake blockers, for example, individuals with Parkinson's disease or attention deficit hyperactivity disorder. Because of the long duration of action of the compounds utilized in the methods of treatment, the intervals between dosing can be lengthened compared with drugs having a shorter duration of action.
  • FIG. 1 is a graph showing the number of ambulation counts resulting from the stimulation of locomotor activity in mice over time by the administration of 1) vehicle; 2) 1 mg/kg of Compound 1; 3) 3 mg/kg of Compound 1; 4) 10 mg/kg of Compound 1; and 5) 30 mg/kg of Compound 1.
  • FIG. 2 is a graph showing the average number of ambulation counts/10 minutes over 30 minutes resulting from the stimulation of locomotor activity in mice versus the dosage of Compound 1 administered to the mice.
  • FIG. 3 is a graph showing the number of ambulation counts resulting from the stimulation of locomotor activity in mice over time by the administration of 1) vehicle; 2) 1 mg/kg of Compound 2; 3) 3 mg/kg of Compound 2; 4) 10 mg/kg of Compound 2; and 5) 30 mg/kg of Compound 2.
  • FIG. 4 is a graph showing the average number of ambulation counts/10 minutes over 30 minutes resulting from the stimulation of locomotor activity in mice versus the dosage of Compound 2 administered to the mice.
  • FIG. 5 is a graph showing the number of ambulation counts resulting from the stimulation of locomotor activity in mice over time by the administration of 1) vehicle; 2) 1 mg/kg of Compound 3; 3) 3 mg/kg of Compound 3; 4) 10 mg/kg of Compound 3; and 5) 30 mg/kg of Compound 3.
  • FIG. 6 is a graph showing the average number of ambulation counts/10 minutes over 30 minutes resulting from the stimulation of locomotor activity in mice by Compound 3 versus the dosage of Compound 3 administered to the mice.
  • FIG. 7 is a graph showing the number of ambulation counts resulting from the stimulation of locomotor activity in mice over time by the administration of 1) vehicle; 2) 1 mg/kg of Compound 4; 3) 3 mg/kg of Compound 4; 4) 10 mg/kg of Compound 4; and 5) 30 mg/kg of Compound 4.
  • FIG. 8 is a graph showing the average number of ambulation counts/10 minutes over 30 minutes resulting from the stimulation of locomotor activity in mice 4 versus the dosage of Compound 4 administered to the mice.
  • FIG. 9 is a graph showing the number of ambulation counts resulting from the stimulation of locomotor activity in mice over time by the administration of 1) vehicle; 2) cocaine; 3) cocaine and 1 mg/kg of Compound 2; 4) cocaine 3 mg/kg of Compound 2; 5) cocaine and 10 mg/kg of Compound 2; and 6) cocaine and 30 mg/kg of Compound 2.
  • FIG. 10 is a graph showing the average number of ambulation counts/10 minutes over 30 minutes over thirty minutes resulting from the stimulation of locomotor activity in mice induced by the administration of 1) vehicle; 2) cocaine; 3) cocaine and 1 mg/kg of Compound 2; 4) cocaine 3 and mg/kg of Compound 2; 5) cocaine and 10 mg/kg of Compound 2; and 6) cocaine and 30 mg/kg of Compound 2.
  • FIG. 11 is a graph showing the locomotor activity in a primate model at 25 minute intervals following the administration of a single dose of 1.0 mg/kg of Compound 1.
  • FIG. 12 is a graph showing the degree of locomotor response in a primate model over a five day period following the administration of a single dose of 1.0 mg/kg of Compound 1.
  • FIG. 13 is a graph showing the number of ambulation counts resulting from the stimulation of locomotor activity in mice over time by the administration of 1) vehicle; 2) 3 mg/kg of Compound 6; 3) 10 mg/kg of Compound 6; 4) 30 mg/kg of Compound 6 and 5) 100 mg/kg of Compound 6.
  • FIG. 14 is a graph showing the average number of ambulation counts/10 minutes over 30 minutes resulting from the stimulation of locomotor activity in mice versus the dosage of Compound 6 administered to the mice.
  • FIG. 15 is a graph showing the number of ambulation counts resulting from the stimulation of locomotor activity in mice over time by the administration of 1) vehicle; 2) 1 mg/kg of Compound 7; 3) 3 mg/kg of Compound 7; 4) 10 mg/kg of Compound 7; 5) 30 mg/kg of Compound 7 and 100 mg/kg of Compound 7.
  • FIG. 16 is a graph showing the average number of ambulation counts/10 minutes over 30 minutes resulting from the stimulation of locomotor activity in mice versus the dosage of Compound 7 administered to the mice.
  • FIG. 17 is a graph showing the number of ambulation counts resulting from the stimulation of locomotor activity in mice over time by the administration of 1) vehicle; 2) cocaine; 3) cocaine and 3 mg/kg of Compound 6; 4) cocaine 10 mg/kg of Compound 6; 5) cocaine and 30 mg/kg of Compound 6; and 6) cocaine and 100 mg/kg of Compound 6.
  • FIG. 18 is a graph showing the average number of ambulation counts/10 minutes over 30 minutes over thirty minutes resulting from the stimulation of locomotor activity in mice induced by the administration of 1) vehicle; 2) cocaine; 3) cocaine and 3 mg/kg of Compound 6; 4) cocaine and 10 mg/kg of Compound 6; 5) cocaine and 30 mg/kg of Compound 6; and 6) cocaine and 100 mg/kg of Compound 6.
  • FIG. 19 is a graph showing the number of ambulation counts resulting from the stimulation of locomotor activity in mice over time by the administration of 1) vehicle; 2) cocaine; 3) cocaine and 3 mg/kg of Compound 7; 4) cocaine 10 mg/kg of Compound 7; 5) cocaine and 30 mg/kg of Compound 7; and 6) cocaine and 100 mg/kg of Compound 7.
  • FIG. 20 is a graph showing the average number of ambulation counts/10 minutes over 30 minutes over thirty minutes resulting from the stimulation of locomotor activity in mice induced by the administration of 1) vehicle; 2) cocaine; 3) cocaine and 3 mg/kg of Compound 7; 4) cocaine and 10 mg/kg of Compound 7; 5) cocaine and 30 mg/kg of Compound 7; and 6) cocaine and 100 mg/kg of Compound 7.
  • FIG. 21 is a graph showing the effect on mice of 1) 5 mg/kg, 2) 10 mg/kg, 3) 20 mg/kg and 4) 40 mg/kg of cocaine compared with saline on horizontal activity counts/10 minute over an eight hour session.
  • FIG. 22 is a graph showing the effect on mice of 1) 1 mg/kg, 2) 3 mg,/kg, 3) 10 mg/kg and 4) 30 mg/kg of Compound 2 compared with saline on horizontal activity counts/10 minute over an eight hour session.
  • FIG. 23A through 23D are graphs showing the effects of Compound 1 on responding maintained by cocaine and food in monkeys 89BO56, WH8, J3A and 89B013.
  • the graph shows the dose of Compound 1 in mg/kg versus the percent control rates of responding maintained by cocaine during the drug component (Drug) and by food during the first food component (Food 1) and the second food component (Food 2) (see Example 7).
  • FIG. 24A through 24C are graphs showing the effects of Compound 1 on the complete cocaine dose-effect curve in monkey 89B056.
  • the graph shows the unit dose cocaine available during the drug component in mg/kg/injection versus the response rate in responses/sec.
  • Panels show data from the drug component (top panel), first food component (middle panel) and second food component (bottom panel) (see Example 7).
  • FIG. 25A through 25C are graphs showing the effects of Compound 1 on the complete cocaine dose-effect curve in monkey WH8.
  • the graph shows the unit dose cocaine available during the drug component in mg/kg/injection versus the response rate in responses/sec.
  • Panels show data from the drug component (top panel), first food component (middle panel) and second food component (bottom panel) (see Example 7).
  • FIG. 26A through 26C are graphs showing the effects of Compound 1 on the complete cocaine dose-effect curve in monkey J3A.
  • the graph shows the unit dose cocaine available during the drug component in mg/kg/injection versus response rate in responses/sec.
  • Panels show data from the drug component (top panel), first food component (middle panel) and second food component (bottom panel) (see Example 7).
  • the compound used in the methods of treatment is represented by Structural Formula (II): ##STR3##
  • R2 is a lower alkyl group or a substituted lower alkyl group, preferably a C1 to C4 straight or branched chain alkyl group.
  • Ring A, R1 and R3-R4 are as described for Structural Formula (I).
  • R5 and R6 are each --H or a substituent, as described for Ring B in Structural Formula (I).
  • the compound used in the methods of treatment is represented by Structural Formula (III): ##STR4##
  • R1-R4 are as defined above for Structural Formula (II).
  • R3 and R4 are preferably each --H and the compound is in the trans configuration. Examples include wherein R1 is methyl, R2 is selected from the group consisting of methyl, ethyl and propyl and R3 and R4 are each --H. Other examples include wherein R1 is methyl, R2 is n-butyl, sec-butyl or tert-butyl and R3 and R4 are each --H.
  • the compound used in the methods of treatment is represented by Structural Formula (II), wherein R2 is a benzyl group or a substituted benzyl group, preferably a benzyl group.
  • Ring A, R1 and R3-R6 are as described for Structural Formula (II).
  • the compound used in the methods of treatment is represented by Structural Formula (III), wherein R2 is a benzyl group or a substituted benzyl group, preferably a benzyl group.
  • R1 and R3--R4 are as described above for Structural Formula (III).
  • R3 and R4 are preferably each --H and the compound is in the trans configuration. Examples include wherein R1 is methyl, R2 is benzyl and R3 and R4 are each --H.
  • An “aryl group” includes carbocyclic aromatic structures.
  • An “aryl group” can be monocyclic (e.g., phenyl) or polycyclic.
  • a polycyclic aromatic group includes moieties having one or more fused carbocyclic aromatic structures, e.g. naphthyl or anthracyl.
  • Suitable heteroaryl groups include monocyclic or polycyclic aromatic groups containing one or more heteroatoms such as oxygen, nitrogen or sulfur.
  • Suitable monocyclic heterocyclic groups include imidazolyl, thienyl, pyridyl, furanyl, oxazoyl, pyrollyl, pyrimidinyl, furanyl, pyrazolyl, pyrrolyl, thiazolyl and the like.
  • a polycyclic heteroaryl group includes fused structures such as quinonyl, isoquinonyl, indoyl benzimidazoyl, benzothiazolyl, benzothiophenyl, benzofuranyl and benzopyranyl.
  • a “lower alkyl group” includes C1 to about C10 straight or branched chain hydrocarbons.
  • the hydrocarbon can be saturated or can have one or more units of unsaturation.
  • Preferred lower alkyl groups are straight chain C1-C3 hydrocarbons.
  • lower alkyl groups preferably include C1 to C4 straight chain and branched hydrocarbons.
  • Suitable substituents for an aryl, heteroaryl, benzyl or lower alkyl group include substituents which do not signifiantly decrease the affinity of the N,N-dialkyl 3-phenyl-1-indamine for the dopamine transporter or the bioavailability of the N,N-dialkyl 3-phenyl-1-indamine.
  • Suitable examples include halogens, lower alkyl, hydroxy, (lower alkyl)-O--, (substituted lower alkyl)-O--, --CN, --NO 2 , --NH 2 , (lower alkyl)NH--, (substituted alkyl)NH--, dialkylamine and (substituted dialkyl)amine.
  • the trans stereoisomer of the compound represented by Structural Formula (I) is preferentially administered.
  • Examples of cis and trans stereoisomers are shown below.
  • the compound can be administered as a racemic mixture of enantiomers, as an optically pure enantiomer or as a mixture enriched in one enantiomer.
  • a “therapeutically effective” amount of a compound is the amount of compound which decreases or alleviates the severity of the symptoms associated with a disease, e.g., Parkinson's disease, attention deficit hyperactivity disorder or cocaine abuse, in an individual being treated with the compound.
  • a “therapeutically effective” amount of a compound can be the amount of compound which decreases the craving for cocaine of an individual who abuses cocaine.
  • a “therapeutically effective amount” of the compound ranges from about 1 mg/day to about 1000 mg/day.
  • the compounds of the present invention can be administered by a variety of known methods, including orally, rectally, or by parenteral routes (e.g., intramuscular, intravenous, subcutaneous, nasal or topical).
  • parenteral routes e.g., intramuscular, intravenous, subcutaneous, nasal or topical.
  • the form in which the compounds are administered will be determined by the route of administration.
  • Such forms include, but are not limited to capsular and tablet formulations (for oral and rectal administration), liquid formulations (for oral, intravenous, intramuscular or subcutaneous administration) and slow releasing microcarriers (for rectal, intramuscular or intravenous administration).
  • the formulations can also contain a physiologically acceptable vehicle and optional adjuvants, flavorings, colorants and preservatives.
  • Suitable physiologically acceptable vehicles may include saline, sterile water, distilled water, Ringer's solution, and isotonic sodium chloride solutions.
  • the specific dosage level of active ingredient will depend upon a number of factors, including, for example, biological activity of the particular preparation, age, body weight, sex and general health of the individual being treated.
  • compositions used in the methods of treatment disclosed herein can contain one N,N-dialkyl 3-1-indanamine.
  • the pharmaceutical composition can contain more than one N,N-dialkyl 3-1-indanamine, e.g. the individual is being administered a mixture of N,N-dialkyl 3-1-indanamines.
  • the individual is being administered a mixture of N,N-dialkyl 3-1-indanamines.
  • virtually any ratio of N,N-dialkyl 3-phenyl-1-indanamines can be used that is non-toxic and therapeutically effective.
  • the compounds of the present invention used in the treatment of an individual with Parkinson's disease or attention deficit hyperactivity disorder can be co-administered with other pharmaceutically active agents used in the treatment of Parkinson's disease or attention deficit hyperactivity disorder.
  • the compounds of the present invention used in the treatment of an individual who abuses cocaine can be combined with other therapies used to treat individuals who abuse cocaine. Such therapies can include the co-administration of other pharmaceutically active agents used to treat cocaine abuse or psychological therapies.
  • the specific combination will vary, depending on a number of factors, including, for example, activity of the agents, their side-effects, and the weight, age, sex and general health of the individual being treated.
  • NaBH 4 (2.46 g) was added in three portions to a mixture of ketone 29 (56.6 g), EtOAc (260 mL), and EtOH (120 mL) with stirring under an Ar atmosphere. After 0.5 h, more NaBH 4 (0.5 g) was added and the stirring was continued for another 0.5 hours. Solvent evaporation under reduced pressure gave a thick dark brown oil. Water (260 mL) was added and the mixture was extracted with EtOAc (260 mL and then 2 ⁇ 80 mL). The combined organic solution was washed with brine and water.
  • the resulting crude product was subjected to purification either by preparative TLC, chromatography, or HPLC with a partial purification either by a silica gel plug or salt formation beforehand.
  • the purification was done as described below.
  • the HCl salt formation from the black oil in a mixture of EtOH, ether, and acetone gave an almond solid enriched with the cis-isomer.
  • the freebase enriched with the trans-isomer were recovered by treatment with saturated Na 2 CO 3 (aq).
  • Maleic acid salt formation from the freebases using EtOAc, EtOH, acetones, hexanes and ether gave a maleic acid salt as a greenish almond solid.
  • Freebase from the mother liquor was again recovered by treatment with saturated Na 2 CO 3 (aq).
  • the recovered freebase was partially purified by passing through a silica gel plug.
  • the recovered freebase, the freebase from the HCl salt, and the freebase from the maleic acid salt were subjected to HPLC separation (Phenomenex Primesphere 5 ⁇ silica 110 column, 250 ⁇ 21.2 mm; UV, 268 nm; 0.05% Et 2 NH/EtOAc, 10 mL/min; cis-isomer, 17 minutes; trans-isomer, 20 minutes) to give pure 32 and 33.
  • Freebases 32 and 33 were converted the their corresponding Hcl, maleic acid or oxalic acid salts.
  • a typical HCl salt formation involved dissolving a freebase in ether, adding 1.1 equivalents of 1 M HCl ether with stirring, vacuum filtration of the resulting suspension, washing the solid with ether and vacuum drying at an appropriate elevated temperature.
  • a typical maleic acid or oxalic salt formation involved dissolving a freebase in ErOH and ether, adding a solution of maleic or oxalic acid (1.05 mol equivalents) in EtOH with stirring, adding more ether to the resulting mixture, vacuum filtration, washing the solid with ether, and vacuum drying at an appropriate elevated temperature.
  • a dose response study of induced locomotor stimulation was conducted according to the following procedure. The study was conducted using a 16 or 32 Digiscan locomotor activity testing chambers (40.5 ⁇ 40.5 ⁇ 30.5 cm) housed in sets of two, within sound-attenuating chambers. A panel of infrared beams (16 beams) and corresponding photodetectors were located in the horizontal direction along the sides of each activity chamber. A 15-W incandescent light above each chamber provided dim illumination. Fans provided an 80-dB ambient noise level within the chamber.
  • FIGS. 1, 3, 5 and 7 show average horizontal activity counts/10 minutes as a function of time, immediately following injection of Compound 1, Compound 2, Compound 3 and Compound 4, respectively.
  • FIGS. 13 and 15 show average horizontal activity counts/10 minutes as a function of time, beginning twenty minutes following injection of Compound 6 and Compound 7, respectively.
  • the period 30-60 minutes was selected for analysis of dose-response data.
  • TableCurve 2D v2.03 software Jandel Scientific
  • the mean average horizontal activity counts/10 minutes for this period were fit to a 3-parameter logistic peak function of log 10 dose (with the constant set to 1989, the mean of the vehicle-treated group), and the maximum effect estimated from the resulting curve.
  • the ED 50 for Compounds 1-6 dose producing 1/2 maximal stimulant activity was estimated from a linear regression against log 10 dose of the ascending portion of the dose-effect curve is shown in Table I below.
  • Compound 7 inhibited locomotor activity; the dose producing 1/2 maximal inhibitory activity ID 50 was 184 mg/kg.
  • FIGS. 2, 4, 6, 8, 14 and 16 show average horizontal activity counts/10 minutes over 30 minutes versus the amount administered of Compound 1, Compound 2, Compound 3, Compound 4, Compound 6 and Compound 7, respectively.
  • FIGS. 9, 17 and 19 show average horizontal activity counts for the different treatment groups as a function of time. The period of 0-30 minutes was selected for analysis of dose-response data because this is the time period in which cocaine produces maximal effects.
  • FIGS. 10, 18 and 20 show average horizontal activity counts/10 min for different treatment groups as a function of dose.
  • the bar above "water” represents the effect of vehicle immediately following saline injection
  • the bar above "cocaine” represents the effect of the 20 mg/kg cocaine immediately following the vehicle injection
  • the bars above “1", “3", “10", and “30” represent the effects of Compound 2 at the designated doses following the cocaine injection.
  • FIGS. 9 show average horizontal activity counts for the different treatment groups as a function of time. The period of 0-30 minutes was selected for analysis of dose-response data because this is the time period in which cocaine produces maximal effects.
  • FIGS. 10, 18 and 20 show average horizontal activity counts/10 min for different treatment groups as a function of dose.
  • the bar above "vehicle” represents the effect of vehicle twenty minutes prior to saline injection
  • the bar above “coc” represents the effect of vehicle twenty minutes prior to 20 mg/kg cocaine injection
  • the bars above "1", “3”, “10", “30” and “100” represent the effects of Compound 6 or Compound 7 at the designated doses twenty minutes prior to 20 mg/kg cocaine injection.
  • Compounds 2, 6 and 7 antagonized the stimulant effect of cocaine and the AD 50 (dose attenuating cocaine-induced stimulation by 50%) was calculated to be 13.76 mg/kg for Compound 2 (3-30 mg/kg Compound 2), 23.6 6 mg/kg Compound 6 (3-100 mg/kg dose range) and 42.5 mg/kg for Compound 7 (3-100 mg/kg dose range).
  • the ordinate value for the AD 50 was calculated using the mean of the vehicle plus 20 mg/kg cocaine (cocaine) group as the maximum value.
  • Compound 1 was tested for its ability to induce a locomotor response in primates according to procedures disclosed in Rosenzweig-Lipson et al., Psychopharmacology 107:186 (1992). Three squirrel monkeys were administered 1.0 mg/kg of Compound 1. The response was measured over 25 minute intervals, as shown in FIG. 11. As observed in mice, Compound 1 induced a slow onset locomotor response. As shown in FIG. 12, the locomotor response in primates peaked at three days. The results for each monkey are shown below in Table III and is presented as the responses per second on each day of the test. Controls were established by testing each monkey prior to administering Compound 1. As can be seen, the increase in response rate lasted for 5-7 days. The experiment was repeated by administering 0.3 mg/kg of Compound 5 to three squirrel monkeys. The results for each monkey are also shown in Table III. As can be seen, the increase in response rate lasted only from about two to four days.
  • a dose response study of induced locomotor stimulation was conducted according to the following procedure. The study was conducted using 16 Digiscan locomotor activity testing chambers (40.5 ⁇ 40.5 ⁇ 30.5 cm) housed in sets of two, within sound-attenuating chambers. A panel of infrared beams (16 beams) and corresponding photodetectors were located in the horizontal direction along the sides of each activity chamber. A 7.5-W incandescent light above each chamber provided dim illumination. Fans provided an 80-dB ambient noise level within the chamber.
  • mice 8 non-habituated male Swiss-Webster mice (Hsd:ND4, aged 2-3 months) were injected via the intraperitoneal (IP) route with either vehicle (0.9% saline) or test compound (5, 10, 20 or 40 mg/kg), immediately prior to locomotor activity testing.
  • IP intraperitoneal
  • horizontal activity interruption of photocell beams was measured for 8 hours within 10 minute periods, beginning at 0880 hours) two hours after lights on). Testing was conducted with one mouse per activity chamber.
  • FIG. 21 shows average horizontal activity counts/10 min as a function of time (0-8 hr) and dose of cocaine (top to bottom panels). Treatment with cocaine resulted in time-dependent stimulation of locomotor activity in doses from 10 to 40 mg/kg. Stimulant effects of 10, 20 and 40 mg/kg occurred within 10 minutes following injection and lasted up to 3 hours. Maximal stimulant effects were evident during the first 30 minutes following 20 mg/kg cocaine, and this period was selected for analysis of dose-response data.
  • a two-way analysis of variance conducted on horizontal activity counts/10 min indicated a significant interaction of Treatment with 10-Minute Periods, as well as a main effect of 10-Minute Periods (ps ⁇ 0.001).
  • FIG. 22 shows average horizontal activity counts/10 min as a function of time (0-8 hr) and dose of Compound 2 (top to bottom panels). Treatment with Compound 2 resulted in time-dependent stimulation of locomotor activity in doses from 3 to 30 mg/kg. Stimulant effects occurred within 40 to 70 minutes following injection and lasted 4 to ⁇ 7 hours. The time period 280-310 min was selected for analysis of dose-response data because this was the time period in which maximal stimulant effects first appeared as a function of dose.
  • the ED 50 dose producing one half maximal stimulant activity was estimated at 3.3 mg/kg from a linear regression against log 10 dose of the ascending portion of the dose-effect curve (1 to 10 mg/kg 30,644).
  • the maximal effect/cocaine maximal effect ratio (ME/CME) was equal to 1.4 based upon the cocaine dose-effect data determined described above.
  • COMPOUND 1 PRODUCES A DOSE-DEPENDENT DECREASE IN COCAINE SELF-ADMINISTRATION IN RHESUS MONKEYS
  • the subjects were four male rhesus monkeys (Macaca mulatta). Each monkey was maintained on a diet of 3-4 monkey biscuits (Purina Monkey Chow Jumbo #5037) and one piece of fresh fruit per day in addition to fruit-flavored pellets delivered during operant sessions (see below). Water was freely available at all times. The monkeys were housed in a humidity and temperature controlled room with a 12 hr light-dark cycle (lights on from 7 a.m. to 7 p.m.).
  • Monkeys were surgically implanted with double-lumen Silicone rubber catheters (inside diameter 0.7 mm; outside diameter 2.0 mm) to facilitate concurrent delivery of cocaine and treatment compounds. Catheters were implanted in the jugular or femoral vein, and the catheters exited in the midscapular region. All surgical procedures were performed under aseptic conditions. Monkeys were initially sedated with ketamine (5 mg/kg, s.c.), and anesthesia was induced with sodium thiopental (10 mg/kg, i.v.). In addition, monkeys were treated with 0.05 mg/kg atropine to reduce salivation. Following insertion of a tracheal tube, anesthesia was maintained with isoflurane (1-1.5% in oxygen).
  • monkeys were administered aspirin or acetaminophen (80-160 mg/day: p.o.) for 3 days.
  • the antibiotic Procaine Penicillin G (300,000 units/day, i.m.) was administered every day for 5 days.
  • the i.v. catheter was protected by a tether system consisting of a custom-fitted nylon vest connected to a flexible stainless steel cable and fluid swivel (Lomir Biomedical; Malone, N.Y.). This flexible tether system permitted monkeys to move freely. Catheter patency was periodically evaluated by i.v.
  • Each monkey was housed individually in a well-ventilated stainless steel chamber(64 ⁇ 64 ⁇ 79 cm).
  • the home cages of all monkeys were modified to include an operant panel (28 ⁇ 28 cm) mounted on the front wall.
  • Three square translucent response keys (6.4 ⁇ 6.4 cm) were arranged 2.54 cm apart in a horizontal row 3.2 cm from the top of the operant panel. Each key could be transilluminated by red or green stimulus lights (Superbright LED's).
  • the operant panel also supported an externally-mounted pellet dispenser (Gerbrands, Model G5210) that delivered 1 gm fruit-flavored food pellets (Precision Primate Pellets Formula L/I Banana Flavor or Precision Purified Pellets Formula L/P Grape Flavor, P. J.
  • Food and i.v. drug or saline injections were available during three alternating components: a 5-min food component, a 100-min drug component, and a second 5-min food component. Both food and i.v. injections were available under a FR30 schedule of reinforcement.
  • the response key was transilluminated red.
  • the drug component was transilluminated green.
  • Following the delivery of each food pellet or drug injection there was a 10 sec timeout period, during which the stimulus light illuminating the center response key was turned off and responding had no scheduled consequences.
  • the food and drug components were separated by 5-min timeout periods when the response key was dark, and responding had no scheduled consequences.
  • the entire food/drug/food session lasted 120 min and was conducted daily from 3-5 p.m.
  • monkeys were also given the opportunity to self-administer additional food pellets during supplementary food sessions running from 7-8 p.m. and 6-7 a.m. During these sessions, food was available under a FR30/Timeout 10 sec schedule, and a maximum of 25 pellets per session could be earned. These food sessions provided enrichment opportunities for the monkeys and behavioral information relevant for the evaluation of prolonged treatment drug effects.
  • the effects of Compound 1 on cocaine and food self-administration were evaluated using the pretreatment test procedure.
  • Compound 1 was administered i.m. 30 min prior to a test session during which a test unit dose of cocaine was available during the drug component of the session.
  • the pretreatment dose of Compound 1 was varied from 0.1 to 3.2 mg/kg, and the unit dose of cocaine was maintained at either 0.0032 mg/kg (monkeys 89B056, 89B013 and J3A) or 0.01 mg/kg/inj (monkey WH8).
  • These unit doses of cocaine were individually selected from the peak of each monkey's cocaine dose-effect curve.
  • test sessions were conducted on Tuesdays and Fridays. Either saline or the maintenance dose of cocaine was available for the remaining sessions during the week. In addition, test days were occasionally omitted to allow several days of saline substitution.
  • the dependent variables were the response rates during each food and drug component.
  • the response rate was calculated as [total number of responses/(component duration-- ⁇ timeouts)].
  • Control response rates for each food and drug component during availability of each unit dose of cocaine were defined as the response rate obtained when that unit dose of cocaine was available and no pretreatment was administered.
  • Cocaine hydrochloride was dissolved in saline.
  • a stock solution of 10 mg/ml Compound 1 was prepared using a vehicle of 50% propylene glycol and 50% distilled water, and dilutions were made with distilled water. Aseptic precautions were taken in every phase of cocaine solution preparation and dispensing.
  • Cocaine solutions were filter-sterilized using an 0.22 micron Millipore Filter and stored in sterile, pyrogen-free vials. Sterility of the entire fluid path for drug solutions was maintained throughout the study.
  • Each unit dose of cocaine was delivered i.v. in an injection volume of 0.1 ml.
  • Doses of Compound 1 were delivered i.m. in a volume of 0.2-3.0 ml.
  • Table IV shows the control rates of cocaine and food-maintained responding during availability of a unit dose of cocaine selected from the peak of each monkey's cocaine dose-effect curve (0.0032 mg/kg/inj in monkeys 89B013, 89B056 and J3A and 0.01 mg/kg/inj cocaine in monkey WH8).
  • FIG. 23 shows the effects of Compound 1 (0.1-3.2 mg/kg) on these control rates of cocaine and food-maintained responding.
  • Compound 1 produced a dose-dependent decrease in rates of cocaine self-administration; however, the dose-effect curve for Compound 1 was relatively shallow across the dose-range tested.
  • FIGS. 24-26 show the effect of 3.2 mg/kg Compound 1 on the complete cocaine dose-effect curves in monkeys 89B056, WH8 and J3A.
  • the top panel in each figure shows response rates during the drug component, the middle panel shows response rates during the first food component (prior to the drug component), and the bottom panel shows response rates during the second food component (following the drug component).
  • the dose-effect curve for cocaine self-administration in each monkey had an inverted-U shape, with maximal rates of cocaine self-administration maintained by unit doses of 0.0032 mg/kg/inj cocaine (monkeys 89B056 and J3A) or 0.01 mg/kg/inj cocaine (monkey WH8).
  • Rates of food-maintained responding were always higher than rates of cocaine self-administration, and across the range of cocaine doses examined, rates of food-maintained responding during the two food components were usually independent of the unit dose of cocaine. The only exception to this general finding occurred in monkey J3A, in which rates of food-maintained responding during the second food component decreased as the unit dose of cocaine available during the drug component increased.
  • Pretreatment with 3.2 mg/kg Compound 1 decreased rates of cocaine self-administration across a wide range of cocaine unit doses while producing relatively minor effects on food-maintained responding in all three monkeys.
  • 3.2 mg/kg Compound 1 decreased rates of cocaine self-administration maintained by cocaine unit doses ranging from 0.0032 to 0.032 mg/kg/inj (FIG. 24). Rates of food-maintained responding were usually unaffected by 3.2 mg/kg Compound 1 in monkey 89B056.
  • monkey WH8 3.2 mg/kg Compound 1 decreased rates of cocaine self-administration maintained by cocaine unit doses of 0.001-0.01 mg/kg/inj (FIG. 25).
  • Compound 1 decreased rates of food-maintained responding to approximately 30% of control levels during the first food component in monkey WH8, but response rates during the second food component were unaffected.
  • Compound 1 decreased responding maintained by 0.001 and 0.0032 mg/kg/inj cocaine and produced small and inconsistent changes in rates of food-maintained responding (FIG. 26).
  • Compound 1 did not produce noticeable overt behavioral effects prior to or during the test session. In addition, Compound 1 usually had no effect on operant response rates on the day following its administration. On some occasions, however, response rates during the food and/or drug components were altered on the day following administration of Compound 1.
  • Compound 1 (0.1-3.2 mg/kg) dose-dependently decreased rates of cocaine self-administration maintained by a unit dose of cocaine located at the peak of the cocaine dose-effect curve in each of four monkeys tested. In addition, 3.2 mg/kg Compound 1 decreased rates of cocaine self-administration across a one to two log unit range of cocaine doses in each of three monkeys tested. Doses of Compound 1 that decreased rates of cocaine self-administration usually decreased rates of food-maintained responding less or increased rates of food-maintained responding. In addition, these doses of Compound 1 did not produce noticeable overt behavioral effects. These findings suggest that Compound 1 can produce selective decreases in cocaine self-administration maintained by a wide range of cocaine unit doses while producing a profile of relatively mild undesirable side effects.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
US08/911,778 1996-08-16 1997-08-15 Slow-onset, long-lasting dopamine reuptake blockers Expired - Fee Related US6011070A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US08/911,778 US6011070A (en) 1996-08-16 1997-08-15 Slow-onset, long-lasting dopamine reuptake blockers

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2409996P 1996-08-16 1996-08-16
US08/911,778 US6011070A (en) 1996-08-16 1997-08-15 Slow-onset, long-lasting dopamine reuptake blockers

Publications (1)

Publication Number Publication Date
US6011070A true US6011070A (en) 2000-01-04

Family

ID=21818864

Family Applications (1)

Application Number Title Priority Date Filing Date
US08/911,778 Expired - Fee Related US6011070A (en) 1996-08-16 1997-08-15 Slow-onset, long-lasting dopamine reuptake blockers

Country Status (4)

Country Link
US (1) US6011070A (fr)
AU (1) AU4078397A (fr)
CA (1) CA2263489A1 (fr)
WO (1) WO1998006689A1 (fr)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001000082A1 (fr) * 1999-06-28 2001-01-04 President And Fellows Of Harvard College Imagerie du transporteur de dopamine afin de determiner tdah
WO2002080957A1 (fr) 2001-04-09 2002-10-17 Neurosearch A/S Traitement de la maladie de parkinson par l'utilisation combinee d'un compose a activite neurotrope et d'un antagoniste du recepteur de l'adenosine a2a
US20020159949A1 (en) * 1995-11-03 2002-10-31 The General Hospital Corporation Methods for diagnosing and monitoring treatment ADHD by assessing the dopamine transporter level
US20060100243A1 (en) * 2004-10-22 2006-05-11 Mark Froimowitz Methylphenidate analogs and methods of use thereof
US20060257316A1 (en) * 1999-05-12 2006-11-16 President And Fellows Of Harvard College Methods for diagnosing and monitoring treatment ADHD by assessing the dopamine transporter level
WO2009036275A1 (fr) * 2007-09-13 2009-03-19 Link Medicine Corporation Traitement de maladies neurodégénératives au moyen d'analogues de l'indatraline
US20100143248A1 (en) * 1999-06-28 2010-06-10 President And Fellows Of Harvard College Methods for diagnosing and monitoring treatment of adhd by assessing the dopamine transporter level

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6525206B1 (en) 2000-10-17 2003-02-25 President And Fellows Of Harvard College Compounds with high monoamine transporter affinity
KR101692047B1 (ko) * 2010-11-30 2017-01-04 연세대학교 산학협력단 오토파지 관련 질환, 혈관신생질환 또는 멜라닌 관련 질환의 예방 또는 치료용 약제학적 조성물

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2339715A1 (de) * 1973-08-06 1975-02-27 Hoechst Ag Basisch substituierte phenylindane und verfahren zu ihrer herstellung
EP0076669A1 (fr) * 1981-10-05 1983-04-13 Kefalas A/S 3-Phényl-1-indanamines, compositions pharmaceutiques et méthodes de préparation
WO1995018617A1 (fr) * 1994-01-10 1995-07-13 Teva Pharmaceutical Industries Ltd. Derives de 1-amino-indane et leurs compositions
US5639913A (en) * 1994-01-10 1997-06-17 Teva Pharmaceutical Industries, Ltd. Method for preparing optically active 1-aminoindan derivatives

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2339715A1 (de) * 1973-08-06 1975-02-27 Hoechst Ag Basisch substituierte phenylindane und verfahren zu ihrer herstellung
EP0076669A1 (fr) * 1981-10-05 1983-04-13 Kefalas A/S 3-Phényl-1-indanamines, compositions pharmaceutiques et méthodes de préparation
WO1995018617A1 (fr) * 1994-01-10 1995-07-13 Teva Pharmaceutical Industries Ltd. Derives de 1-amino-indane et leurs compositions
US5639913A (en) * 1994-01-10 1997-06-17 Teva Pharmaceutical Industries, Ltd. Method for preparing optically active 1-aminoindan derivatives

Non-Patent Citations (13)

* Cited by examiner, † Cited by third party
Title
Eliot L. Gardner, et al., Poster presented at meetings of The College on Problems of Drug Dependence, Nashville, Tennessee, Jun. 1997. *
K. P. Bogeso, et al., 3 Phenyl 1 Indanamines Potential Antidepressant Activity and Potent Inhibition of Dopamine, Norepinephrine and Serotonin Uptake, J. Med. Chem., 28:1817 1828 (1985). *
K. P. Bogeso, et al., 3-Phenyl-1-Indanamines Potential Antidepressant Activity and Potent Inhibition of Dopamine, Norepinephrine and Serotonin Uptake, J. Med. Chem., 28:1817-1828 (1985).
M. Froimowitz, et al., "Effects of a Slow-Onset, Long-Acting Dopamine Reuptake Blocker on Cacaine Self-Administration and on Nucleus Accumbens Dopamine," Society for Neuroscience Abstracts, vol. 23, Part. 1, 27th Annual Meeting, New Orleans, LA, Oct. 25-30, 1997, Mail Date: Aug. 25, 1997.
M. Froimowitz, et al., "Slow Onset, Long Lasting Dopamine Reuptake Blockers as Potential Medications for the Treatment of Cocaine Abuse," 1996 Annual Meeting, Washington, D.C., Nov. 16-21, 1996, Abstract, Mail Date: Aug. 18, 1996.
M. Froimowitz, et al., Effects of a Slow Onset, Long Acting Dopamine Reuptake Blocker on Cacaine Self Administration and on Nucleus Accumbens Dopamine, Society for Neuroscience Abstracts, vol. 23, Part. 1, 27 th Annual Meeting, New Orleans, LA, Oct. 25 30, 1997, Mail Date: Aug. 25, 1997. *
M. Froimowitz, et al., Slow Onset, Long Lasting Dopamine Reuptake Blockers as Potential Medications for the Treatment of Cocaine Abuse, 1996 Annual Meeting, Washington, D.C., Nov. 16 21, 1996, Abstract, Mail Date: Aug. 18, 1996. *
N. Tomita, "Structure--Activity Relationships of Dopamine--and Norepinephrine-Uptake Inhibitors," Chem. Pharm. Bull. 38(6):1563-1569 (1990).
N. Tomita, Structure Activity Relationships of Dopamine and Norepinephrine Uptake Inhibitors, Chem. Pharm. Bull. 38 ( 6 ):1563 1569 (1990). *
S. Izenwasser, et al., "Differential Relationships Among Dopamine Transporter Affinities and Stimulant Potencies of Various Uptake Inhibitors," European Journal of Pharmacology, 263:277-283 (1994).
S. Izenwasser, et al., Differential Relationships Among Dopamine Transporter Affinities and Stimulant Potencies of Various Uptake Inhibitors, European Journal of Pharmacology, 263:277 283 (1994). *
S. Rosonzweig Lipson et al., Stereoselective Behavioral Effects of Lu 19 005 in Monkeys: Relation to Binding at Cocaine Recognition Sites, Psychopharmacology, 107:186 194 (1992). *
S. Rosonzweig-Lipson et al., "Stereoselective Behavioral Effects of Lu 19-005 in Monkeys: Relation to Binding at Cocaine Recognition Sites," Psychopharmacology, 107:186-194 (1992).

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020159949A1 (en) * 1995-11-03 2002-10-31 The General Hospital Corporation Methods for diagnosing and monitoring treatment ADHD by assessing the dopamine transporter level
US7081238B2 (en) 1995-11-03 2006-07-25 The President And Fellows Of Harvard College Methods for diagnosing and monitoring treatment ADHD by assessing the dopamine transporter level
US20060257316A1 (en) * 1999-05-12 2006-11-16 President And Fellows Of Harvard College Methods for diagnosing and monitoring treatment ADHD by assessing the dopamine transporter level
US7553478B2 (en) 1999-05-12 2009-06-30 President And Fellows Of Harvard College Methods for diagnosing and monitoring treatment ADHD by assessing the dopamine transporter level
WO2001000082A1 (fr) * 1999-06-28 2001-01-04 President And Fellows Of Harvard College Imagerie du transporteur de dopamine afin de determiner tdah
US20100143248A1 (en) * 1999-06-28 2010-06-10 President And Fellows Of Harvard College Methods for diagnosing and monitoring treatment of adhd by assessing the dopamine transporter level
WO2002080957A1 (fr) 2001-04-09 2002-10-17 Neurosearch A/S Traitement de la maladie de parkinson par l'utilisation combinee d'un compose a activite neurotrope et d'un antagoniste du recepteur de l'adenosine a2a
US20060100243A1 (en) * 2004-10-22 2006-05-11 Mark Froimowitz Methylphenidate analogs and methods of use thereof
WO2009036275A1 (fr) * 2007-09-13 2009-03-19 Link Medicine Corporation Traitement de maladies neurodégénératives au moyen d'analogues de l'indatraline
US20100292292A1 (en) * 2007-09-13 2010-11-18 Link Medicine Corporation Treatment of Neurodegenerative Diseases Using Indatraline Analogs

Also Published As

Publication number Publication date
CA2263489A1 (fr) 1998-02-19
AU4078397A (en) 1998-03-06
WO1998006689A1 (fr) 1998-02-19

Similar Documents

Publication Publication Date Title
CA2764665C (fr) Compositions de traitement de la dependance aux drogues et d'amelioration du comportement lie aux dependances
EP1634498B1 (fr) Formulation d'exo-S-mecylamine
DE69434872T2 (de) Neue Behandlungsmethoden durch Verwendung von Phenethylderivaten
KR100858232B1 (ko) 카바메이트 화합물을 포함하는 거동 장애 예방 또는 치료용 약제학적 조성물
DE60107435T2 (de) 2-adamantylethylamine und deren verwendung bei der behandlung von abnormalitäten in der glutamat transmission
US6011070A (en) Slow-onset, long-lasting dopamine reuptake blockers
KR20090107500A (ko) 동통질환 치료제
CN101332292A (zh) 肽类化合物用于治疗非神经性炎性疼痛的新用途
AU2021215274B2 (en) Targeted drug rescue with novel compositions, combinations, and methods thereof
CA2373797A1 (fr) Methodes de traitement ou de prevention des troubles affectifs
US11981617B2 (en) Ketamine pamoate and use thereof
US8049038B2 (en) Carnitine conjugates of adamantanamines derivatives as dual prodrugs for various uses
CN1382145A (zh) 神经性疼痛治疗剂和神经性疼痛的动物模型
JP2016537432A (ja) 神経変性疾患の処置に有用なウィザノライド
JP2514163B2 (ja) ピリミドン誘導体及び類似化合物を含有する、喘息又は炎症性気道疾患の治療用医薬組成物
CN1044367C (zh) (S)－α－苯基－2－吡啶乙胺,其制法及含该化合物的组合物
JP2877231B2 (ja) スピロキヌクリジン誘導体の光学異性体、それらの製造法、それらからなる薬剤組成物およびそれらを使用した治療法
CN1051226C (zh) 使用三环化合物制备治疗记忆识别失调的药物
AU2004212328B2 (en) Use of S-10 hydroxy-10, 11-dihydro-carbamazepine for the treatment of anxiety and bipolar disorders
CH637370A5 (en) Racemic forms and optically active forms of 2-(4-biphenylyl)-N-(diethylaminoalkyl)-propionamide, salts thereof and relative preparation processes
US5821386A (en) Compounds for treating cocaine abuse
CA2551575A1 (fr) Derives de benzopyrane, procede de production et d'utilisation de ceux-ci
CA2373856C (fr) Sulfures, sulfoxydes et sulfones de 1-arylcycloalkyle pour le traitement de la consommation de drogues a mauvais escient ou de maladies addictives
CN112516130B (zh) 一种长效低成瘾性化合物在制备药物中的应用
EP0345883A2 (fr) Utilisation de dapiprazole pour la production d'une composition pharmaceutique pour inhiber le développement de la tolérance dans le traitement analgésique avec de la morphine

Legal Events

Date Code Title Description
AS Assignment

Owner name: ALLELIX-PHARM-ECO L.P., MASSACHUSETTS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:WU, KUO-MING;REEL/FRAME:009050/0874

Effective date: 19980312

CC Certificate of correction
FPAY Fee payment

Year of fee payment: 4

SULP Surcharge for late payment
REMI Maintenance fee reminder mailed
REMI Maintenance fee reminder mailed
LAPS Lapse for failure to pay maintenance fees
STCH Information on status: patent discontinuation

Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362

FP Lapsed due to failure to pay maintenance fee

Effective date: 20080104

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载